ClinicalTrials.gg
CompletedNCT04481997ARTHEMISUpdated Aug 29, 2025

Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCI

An observational study in Type2 Diabetes Mellitus and Coronary Heart Disease, sponsored by Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA. Completed at 12 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Coronary Disease with a site in Portugal — 2 open to participants now, 3 under way, none of them phase 3. Coronary Disease · Portugal.

Started
2021
with 1 other
Observational
3 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA

Among the 13 studies in Coronary Disease with a site in Portugal, this one is one of 2 that started in 2021, is one of 3 observational ones, and was the 12th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

2 of the 13 studies in Coronary Disease with a site in Portugal are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Coronary Disease with a site in Portugal, or all of them as a file.
02

Study summary

Diabetes mellitus (DM) is one of the main risk factors for ischemic events in patients with coronary artery disease (CAD) and diabetes is a factor in several post-PCI (Percutaneous Coronary Intervention) risk scores. However, until recently, there were almost no studies performed specifically in the diabetic population of patients undergoing PCI. This study aims to describe the anti-thrombotic regimens, clinical outcomes and current diabetes medical treatment in an unselected consecutive population of patients with DM undergoing PCI.

Read the detailed description

Diabetes is one of the main risk factors for ischemic events in patients with coronary artery disease and diabetes is a factor in several post-PCI risk scores (including the commonly used DAPT score). However, until recently, there were almost no studies performed specifically in the diabetic population of patients undergoing PCI. At large, results from randomized trials assessing the duration of DAPT have produced conflicting results and there is uncertainty about the best anti-thrombotic strategy in patients with diabetes. Further assessment of the patterns of use and their clinical effects, including those related to prolonged DAPT is needed, in diabetic patients, especially in less selected "real world" populations.

03

Conditions studied

  • Type2 Diabetes Mellitus
  • Coronary Heart Disease

Keywords

  • PCI-Percutaneous Coronary Intervention
  • Diabetes Mellitus
  • Dual Antiplatelet Therapy
  • Anti-diabetic drugs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

1000 Type 2 Diabetes mellitus consecutive patients submitted to PCI in 12 interventional Cardiology Portuguese centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PCI with stent implantation, performed in at least one major coronary artery in the context of stable coronary artery disease or acute coronary syndrome
  • Type 2 Diabetes mellitus (previously diagnosed or diagnosed at the index admission)
  • signed
  • Patient not simultaneously participating in any interventional study

Exclusion criteria

Exclusion Criteria:

  • Patients with Type 1 Diabetes mellitus
  • Patients whose survival is expected to be lower than 1 year at hospital discharge
  • Patients not whiling to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Diabetic patients with CAD submitted to PCI

    Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI

    Other: Exposure to Anti-thrombotic treatment agents and glucose lowering therapy

Interventions

  • OtherExposure to Anti-thrombotic treatment agents and glucose lowering therapy

    Exposure to Anti-thrombotic treatment agents and glucose lowering therapy

06

What researchers measure

Primary outcomes

  1. Enumeration of the anti-thrombotic agents prescribed to patients

    Time frame: Baseline to 24 months follow-up

  2. Planned duration of dual anti-platelet treatment (DAPT) after the PCI.

    Time frame: From index admission to 24 months follow-up

  3. Adherence to anti-thrombotic regimen

    Classified qualitatively according to the assessment of the attending physician.

    Time frame: 6 to 24 months follow-up

  4. Actual duration of DAPT (if different from the planned duration)

    Time frame: 6 to 24 months follow-up

  5. Reasons for interrupting DAPT at a time different from the planned duration

    Time frame: 6 to 24 months follow-up

  6. Reasons for prolonging DAPT over 1 year

    Time frame: 12 to 24 months follow-up

Secondary outcomes

  1. Major Adverse Coronary Events (MACE)

    Major Adverse Coronary Events (MACE) (death from any cause, new spontaneous acute myocardial infarction, stroke).

    Time frame: 6 to 24 months follow-up

  2. Death rate from any cause

    Time frame: 6 to 24 months follow-up

  3. Rate of cardiovascular death

    Time frame: 6 to 24 months follow-up

  4. Rate of new spontaneous acute myocardial infarction

    Time frame: 6 to 24 months follow-up

  5. Rate of hospital admissions for acute coronary infarction

    Time frame: 6 to 24 months follow-up

  6. Rate of unplanned coronary revascularization

    Time frame: 6 to 24 months follow-up

  7. Rate of stroke/transient ischemic attack

    Time frame: 6 to 24 months follow-up

  8. Death rate from heart failure

    Time frame: 6 to 24 months follow-up

  9. Rate of hospital admission due to heart failure

    Time frame: 6 to 24 months follow-up

  10. Rate of bleeding events of type 3-5 of BARC (Bleeding Academic Research Consortium) scale

    The BARC (Bleeding Academic Research Consortium) scale will be used. The minimum and maximum scores of the scale are, respectively, type 0 (no bleeding) and type 5 (fatal). There will only be collected the events corresponding to type 3-5 of BARC scale.

    Time frame: 6 to 24 months follow-up

  11. Rate of bleeding events of type 1-5 of BARC (Bleeding Academic Research Consortium) scale

    The BARC (Bleeding Academic Research Consortium) scale will be used. The minimum and maximum scores of the scale are, respectively, type 0 (no bleeding) and type 5 (fatal). There will be collected the events corresponding to type 1-5 of BARC scale.

    Time frame: 6 to 24 months follow-up

  12. Percentage of patients treated with different glucose-lowering drugs.

    Time frame: Before index admission to 24 months follow-up.

  13. Diabetes control (HbA1c values)

    Time frame: At baseline to 24 months follow-up

07

Study locations

12 sites
  • Hospital de Braga, EPE
    Braga, Braga District 4710-243, Portugal
  • Centro Hospitalar e Universitário de Coimbra - Hospital Geral & Hospital Universitário de Coimbra
    Coimbra, Coimbra District 3000-075, Portugal
  • Centro Hospitalar Universitário do Algarve - Hospital de Faro
    Faro, Faro District 8000-386, Portugal
  • Hospital Prof. Doutor Fernando Fonseca
    Amadora, Lisbon District 2720-276, Portugal
  • Centro Hospitalar Lisboa Ocidental - Hospital de Santa Cruz
    Carnaxide, Lisbon District 2790-134, Portugal
  • Centro Hospitalar Lisboa Central - Hospital de Santa Marta
    Lisbon, Lisbon District 1159-064, Portugal
  • Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria
    Lisbon, Lisbon District 1649-035, Portugal
  • Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António
    Porto, Porto District 4099-001, Portugal
  • Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE
    Vila Nova de Gaia, Porto District 4434-502, Portugal
  • Hospital Garcia de Orta
    Almada, Setúbal District 2805-267, Portugal
  • Centro Hospitalar de Setúbal
    Setúbal, Setúbal District 2910-549, Portugal
  • Hospital do Espírito Santo de Évora, EPE
    Evora, Évora District 7000-811, Portugal
08

References and documents

Publications

  • Bravo Baptista S, Pires de Morais G, Almeida Morais L, Costa J, Vinhas H, Campos G, Carrilho Ferreira P, Vale N, Seixo F, Santos M, Martins C, Rodrigues Bras D, Alexandre A, Raposo L. Anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI with stent implantation: A prospective multicenter observational study on prescription patterns and clinical outcomes. Baseline inclusion data of the ARTHEMIS registry. Rev Port Cardiol. 2025 Sep;44(9):537-546. doi: 10.1016/j.repc.2025.03.006. Epub 2025 Jul 28. English, Portuguese. PubMed 40738464 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2023, 33 months.

Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's 33 months is below that.

Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jul 22, 2020
StartActual
Jan 11, 2021
Primary completionActual
Nov 4, 2023
CompletionActual
Jan 30, 2024
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04481997
Lead sponsor
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA
Collaborators
AstraZeneca, Cardiovascular Centre of Universidade de Lisboa (CCUL)
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Jan 11, 2021
Primary completion
Nov 4, 2023
Completion
Jan 30, 2024
Last update
Aug 29, 2025

Study contacts

Sérgio B Baptista, PhD
principal investigator · Cardiovascular Centre of the University of Lisbon (CCUL)
Luís Raposo, MD
principal investigator · Hospital de Santa Cruz, CHLO, EPE, Lisbon, Portugal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion